A Cambridge biotechnology company developing a treatment for a severe form of muscular dystrophy that progresses rapidly presented three years of data Thursday that show the drug is helping to slow the effects of the fatal, muscle-wasting disease.
With the positive results, Sarepta Therapeutics will seek approval from the Food and Drug Administration later this year with the goal of selling the drug, called eteplirsen, in 2015, to treat the disease known as Duchenne muscular dystrophy. If approved, it would be Sarepta’s first commercial drug.
“We’re very encouraged by this data,” Sarepta’s chief executive, Chris Garabedian, said in an interview. “This is more evidence that the FDA can look at to positively review eteplirsen’s treatment benefits.”
Duchenne muscular dystrophy occurs in about 1 of every 3,500 boys, destroying muscle function and quality of life over time. The disease moves swiftly, robbing most boys of the ability to walk by their teen years, and damaging their respiratory muscles. Duchenne patients typically do not live past their 20s.
This article has been extracted from http://www.bostonglobe.com, please click on this link to read the article in full http://www.bostonglobe.com/business/2014/07/10/data-shows-cambridge-biotech-muscular-dystrophy-treatment-effective/8qULRRssaguT8qFw26tqXP/story.html
Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:
ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.
With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.